Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer

Eelke H. Gort, Karijn P M Suijkerbuijk, Suzan M. Roothaan, Venu Raman, Marc Vooijs, Elsken Van Der Wall, Paul J. Van Diest

Research output: Contribution to journalArticle

Abstract

TWIST1, an antiapoptotic and prometastatic transcription factor, is overexpressedin many epithelial cancers including breast. Only little is known regarding the regulation of TWIST1 in these cancers. Recently, an increase in the TWIST1 promoter methylation has been shown in breast cancers. To correlate the percentage of TWIST1 promoter methylation to the protein levels, we analyzed simultaneously the methylation status as well as the mRNA and the percentage of cells expressing TWIST1 in normal breast tissue and 76 invasive breast cancers. We found that TWIST1 promoter methylation is significantly more prevalent in malignant compared with healthy breast tissue. Furthermore, the percentage of cells expressing TWIST1 was greater in breast malignancy compared with matched healthy tissue from the same patients. There was no correlation, however, between TWIST1 promoter methylation and TWIST1 protein or RNA expression. This indicates that although TWIST1 CpG methylation is useful as a biomarker in breast cancer diagnosis, there is no direct correlation with TWIST1 expression.

Original languageEnglish (US)
Pages (from-to)3325-3330
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume17
Issue number12
DOIs
StatePublished - Dec 2008

Fingerprint

Methylation
Breast Neoplasms
Messenger RNA
Breast
Twist-Related Protein 1
Neoplasms
Transcription Factors
Biomarkers
RNA
Proteins

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer. / Gort, Eelke H.; Suijkerbuijk, Karijn P M; Roothaan, Suzan M.; Raman, Venu; Vooijs, Marc; Van Der Wall, Elsken; Van Diest, Paul J.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 17, No. 12, 12.2008, p. 3325-3330.

Research output: Contribution to journalArticle

Gort, Eelke H. ; Suijkerbuijk, Karijn P M ; Roothaan, Suzan M. ; Raman, Venu ; Vooijs, Marc ; Van Der Wall, Elsken ; Van Diest, Paul J. / Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2008 ; Vol. 17, No. 12. pp. 3325-3330.
@article{81667fec84704c188adfce88dc98de98,
title = "Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer",
abstract = "TWIST1, an antiapoptotic and prometastatic transcription factor, is overexpressedin many epithelial cancers including breast. Only little is known regarding the regulation of TWIST1 in these cancers. Recently, an increase in the TWIST1 promoter methylation has been shown in breast cancers. To correlate the percentage of TWIST1 promoter methylation to the protein levels, we analyzed simultaneously the methylation status as well as the mRNA and the percentage of cells expressing TWIST1 in normal breast tissue and 76 invasive breast cancers. We found that TWIST1 promoter methylation is significantly more prevalent in malignant compared with healthy breast tissue. Furthermore, the percentage of cells expressing TWIST1 was greater in breast malignancy compared with matched healthy tissue from the same patients. There was no correlation, however, between TWIST1 promoter methylation and TWIST1 protein or RNA expression. This indicates that although TWIST1 CpG methylation is useful as a biomarker in breast cancer diagnosis, there is no direct correlation with TWIST1 expression.",
author = "Gort, {Eelke H.} and Suijkerbuijk, {Karijn P M} and Roothaan, {Suzan M.} and Venu Raman and Marc Vooijs and {Van Der Wall}, Elsken and {Van Diest}, {Paul J.}",
year = "2008",
month = "12",
doi = "10.1158/1055-9965.EPI-08-0472",
language = "English (US)",
volume = "17",
pages = "3325--3330",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer

AU - Gort, Eelke H.

AU - Suijkerbuijk, Karijn P M

AU - Roothaan, Suzan M.

AU - Raman, Venu

AU - Vooijs, Marc

AU - Van Der Wall, Elsken

AU - Van Diest, Paul J.

PY - 2008/12

Y1 - 2008/12

N2 - TWIST1, an antiapoptotic and prometastatic transcription factor, is overexpressedin many epithelial cancers including breast. Only little is known regarding the regulation of TWIST1 in these cancers. Recently, an increase in the TWIST1 promoter methylation has been shown in breast cancers. To correlate the percentage of TWIST1 promoter methylation to the protein levels, we analyzed simultaneously the methylation status as well as the mRNA and the percentage of cells expressing TWIST1 in normal breast tissue and 76 invasive breast cancers. We found that TWIST1 promoter methylation is significantly more prevalent in malignant compared with healthy breast tissue. Furthermore, the percentage of cells expressing TWIST1 was greater in breast malignancy compared with matched healthy tissue from the same patients. There was no correlation, however, between TWIST1 promoter methylation and TWIST1 protein or RNA expression. This indicates that although TWIST1 CpG methylation is useful as a biomarker in breast cancer diagnosis, there is no direct correlation with TWIST1 expression.

AB - TWIST1, an antiapoptotic and prometastatic transcription factor, is overexpressedin many epithelial cancers including breast. Only little is known regarding the regulation of TWIST1 in these cancers. Recently, an increase in the TWIST1 promoter methylation has been shown in breast cancers. To correlate the percentage of TWIST1 promoter methylation to the protein levels, we analyzed simultaneously the methylation status as well as the mRNA and the percentage of cells expressing TWIST1 in normal breast tissue and 76 invasive breast cancers. We found that TWIST1 promoter methylation is significantly more prevalent in malignant compared with healthy breast tissue. Furthermore, the percentage of cells expressing TWIST1 was greater in breast malignancy compared with matched healthy tissue from the same patients. There was no correlation, however, between TWIST1 promoter methylation and TWIST1 protein or RNA expression. This indicates that although TWIST1 CpG methylation is useful as a biomarker in breast cancer diagnosis, there is no direct correlation with TWIST1 expression.

UR - http://www.scopus.com/inward/record.url?scp=57449112113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57449112113&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-08-0472

DO - 10.1158/1055-9965.EPI-08-0472

M3 - Article

VL - 17

SP - 3325

EP - 3330

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 12

ER -